Activity of antiandrogens against juvenile and adult Schistosoma mansoni in mice

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 9, 2010, Pages 1991-1995

  Keiser, Jennifer ^a,b   Vargas, Mireille ^a,b   Vennerstrom, Jonathan L ^c  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Bicalutamide; Cyproterone acetate; Flutamide; Nilutamide; Schistosomiasis

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; FLUTAMIDE; NILUTAMIDE; PRAZIQUANTEL; STEROID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHELMINTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MONITORING; EXPERIMENTAL MOUSE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; REDUCTION; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SINGLE DRUG DOSE; WORM;

EID: 77955651005     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq233     Document Type: Article

References (10)

1. Steinmann P, Keiser J, Bos R et al. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006; 6: 411-25.
2. Caffrey CR, Williams DL, Todd MJ et al. Chemotherapeutic development strategies for schistosomiasis. In: Selzer PM, ed. Antiparasitic and Antibacterial Drug Discovery. Weinheim: Wiley-Blackwell, 2009; 301-21.
3. Keiser J. In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology 2010; 137: 589-603.
4. Luttermoser GW, Bond HW. Results of laboratory screening tests of compounds for possible schistosomicidal agents. I. Rhodanidines and hydantoins. J Parasitol 1954; 40: 33.
5. Link H, Stohler HR. 3-Arylhydantoine, eine substanzklasse mit schistosomizider wirkung. Eur J Med Chem 1984; 19: 261-5.
6. Gao W, Dalton JT. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today 2007; 12: 241-8.
7. Nwaka S, Ramirez B, Brun R et al. Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl Trop Dis 2009; 3: e440.
8. Mahler C, Verhelst J, Denis L. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Clin Pharmacokinet 1998; 34: 405-17.
9. Escobedo G, Roberts CW, Carrero JC et al. Parasite regulation by host hormones: an old mechanism of host exploitation? Trends Parasitol 2005; 21: 588-93.
10. Migliari R, Muscas G, Murru M et al. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy. Arch Ital Urol Androl 1999; 71: 293-302.